The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics

Fimasartan, the eighth angiotensin receptor blocker, was launched in March 2011 and was found to have an excellent efficacy and safety profile in a large cross-sectional population study [Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb); Park et al.: Am J Cardio...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Changsoo, Kim, Min Young, Kang, Dae Ryong, Kim, Jang-Young, Park, Jeong Bae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315348/
https://www.ncbi.nlm.nih.gov/pubmed/26587436
http://dx.doi.org/10.1159/000360965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315348/
https://www.ncbi.nlm.nih.gov/pubmed/26587436
http://dx.doi.org/10.1159/000360965

Ejemplares similares